The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

NCT04104607 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostatic Cancer

Interventions

DRUG: CC-1, PSMAxCD3

Sponsor

University Hospital Tuebingen

Collaborators

[object Object]